key: cord-0936153-m3uylwu9
authors: Lalani, Salima; Gew, Lai Ti; Poh, Chit Laa
title: Antiviral Peptides against Enterovirus A71 causing Hand, Foot and Mouth Disease
date: 2020-11-07
journal: Peptides
DOI: 10.1016/j.peptides.2020.170443
sha: 4bb686ba3897851df4836249e492ebd627425de6
doc_id: 936153
cord_uid: m3uylwu9

The emergence of new and resistant viruses is a serious global burden. Conventional antiviral therapy with small molecules has led to the development of resistant mutants. In the case of hand, foot and mouth disease (HFMD), the absence of a US-FDA approved vaccine calls for urgent need to develop an antiviral that could serve as a safe, potent and robust therapy against the neurovirulent Enterovirus A71 (EV-A71). Natural peptides such as lactoferrin, melittin and synthetic peptides such as SP40, RGDS and LVLQTM have been studied against EV-A71 and have shown promising results as potent antivirals in pre-clinical studies. Peptides are considered safe, efficacious and pose fewer chances of resistance. Poor pharmacokinetic features of peptides can be overcome by the use of chemical modifications to improve in vivo delivery particularly by oral route. The use of nanotechnology can remarkably assist in the oral delivery of peptides and enhance stability in vivo. This can greatly increase patient compliance and make it more attractive as antiviral therapy.

The emergence and re-emergence of viral pathogens capable of causing epidemics or pandemics pose urgent attention to the research community to develop novel vaccines and antivirals. The development of an effective and safe vaccine against novel emerging pathogens is especially challenging and time-consuming. In the recent pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) causing coronavirus disease , it is estimated that it will take from 18 months to two years to develop an effective vaccine with an efficacy of 50% [1] . This is the shortest time frame envisaged for the development of an effective and safe vaccine at pandemic speed to prevent further escalations of the contagion, unlike and normal research process for vaccine development which may take up to 10 years. An alternative to prevent or treat viral infections is to focus on the development of antiviral drugs which, in absence of an effective vaccine, could be valuable to prevent or treat the infections.

Enterovirus A71 (EV-A71) is one of the main etiological agents of hand, foot and mouth disease (HMFD). Other HFMD pathogens that have caused major outbreaks include Coxsackievirus-A16 (CV-A16), Coxsackievirus-A10 (CV-A10) and Coxsackievirus-A6 (CV-A6). However, EV-A71 has been proven to be a neurotropic virus capable of causing severe neurological syndromes with high fatalities in Asia [2] . To date, there is no US-FDA Food and Drug Administration (FDA) approved vaccine or antiviral therapy for neurovirulent EV-A71 causing HFMD. The FDA has approved nearly 100 antiviral drugs for different viral infections over the past 50 years. More than half of these antivirals are used to treat human immunodeficiency virus infection-1 (HIV-1), influenza virus, herpes simplex virus (HSV) and hepatitis B and C viruses [3] . 

Antivirals can be isolated from natural sources such as plants, microorganisms, mammals, arthropods and marine organisms. These antivirals have made their way to clinical therapeutics such as podophyllotoxin for perianal and genital warts, oseltamivir for influenza virus and tenofovir for hepatitis B virus (HBV) and human immunodeficiency virus infection (HIV) [4, 5] . Vidarabine is another FDA-approved antiviral that interferes with viral DNA replication but was discontinued in 2001 due to solubility and rapid degradation issues [3] .

Oxymetrin from Sophora flavescens was shown to be a promising antiviral agent against coxsackie B3-virus induced myocarditis in mice [6] . Moreover, there are many flavonoids with varied antiviral mechanisms of action that have been recently reviewed [7] . However, the isolation and purification of natural antiviral compounds from plants or mammals is a long, laborious, time-consuming and expensive process [8] .

Small molecules have made tremendous advancement in the antiviral field in recent years. Most of the small molecules can enter the cell conveniently and elicit downstream interactions due to their small size. Small molecules can modify protein functions and alter protein-protein interactions. Many small molecules have been developed to treat viral infections. Some of these have been successfully used to treat viral infections while others are undergoing pre-clinical and clinical trials.

Recently approved small molecules by FDA (from 2018 onwards) for viral infections include tecovirimat for smallpox, baloxavir marboxil for influenza viruses and doravirine and bictegravir for HIV-1 and HIV-2 infections, respectively (www.fda.gov). Pimodivir is a small J o u r n a l P r e -p r o o f 6 molecule that is in phase III clinical trials for influenza infections [9] . Likewise, for HIV, many small molecules such as LA Cabotegravir, Elsulfavirine and Fostemsavir are currently under phase III clinical trials [10] [11] [12] . Apart from off-target toxicities owing to adverse drug effects to patients, the major problem associated with small molecules is resistance posed by viruses. Therefore, there is a need to identify antiviral agents that are more specifically targeted, less susceptible to resistance and with fewer side effects. For an antiviral to be useful and has limited side effects, its target and mechanism of action must be thoroughly understood. The ideal target will be a viral process that is essential for the replication of the virus so that it cannot mutate to form escape mutants. If the virus will mutate at crucial positions, it will have to compromise its fitness and therefore, its survival.

Peptides are now widely accepted as drugs and there is an increasing number of peptides that are being tested as antimicrobial agents in clinical trials [13] . Table 1 

The main advantages of peptides over small chemical compounds are specificity, tolerability, potency, rarer side effects (as the final breakdown products are amino-acids) and commercial scalability. Moreover, peptides have the potential to interact at the active site of large proteins where protein-protein interaction is essential. Lead identification has been much easier now with advancements in structural and genomic technologies.

However, the short half-life, solubility, bioavailability, stability as well as delivery of J o u r n a l P r e -p r o o f natural peptides are major challenges faced by peptides. These could be overcome by physicochemical and structural alterations during formulation development to make peptides more acceptable as therapeutics and are discussed in section 5 of the review. The delivery of antiviral drugs has been improved by nanocarriers. In addition, nanoparticles have led to enhanced bioavailability and modified pharmacokinetics [22] .

FDA has approved many peptides that are currently being used as therapeutics. For example, vancomycin is generally prescribed in clinical practice to treat resistant bacterial infections. Bacitracin and Neosporin are known peptides given to infants to treat pneumonia and other staphylococcal infections by external applications [23] .

Although small molecules have made great medicinal progression in the preceding century, it has brought along with it the uncertainties of resistance. In the case of antivirals, the efficiency of small molecules has been repeatedly hampered by the emergence of resistant mutants. These mutated viruses pose dangers of re-emergence of viral infections that could become a global challenge. Influenza virus -a causative agent of seasonal flu, has frequently mutated over the years and rendered many anti-influenza drugs futile. For example, resistance towards antivirals such as amantadine, rimantadine, zanamivir and oseltamivir has emerged [24] . Moreover, relatively newer approved antivirals for influenza such as baloxavir marboxil (Xofluza) and peramivir (Rapivab) have to be used with caution to avoid resistance.

Another instance where resistance to small molecules has hampered the development of antivirals is in the case of the respiratory syncytial virus. Virus escape mutants were soon identified in tissue cultures and the general population against small molecules (GS-5806, RV-521 and JNJ-53718678) due to viral mutations such as P488I/V, D486N, D498Y and L141W. Some of these mutations contributed to reduced fitness of the virus while others helped to increase or maintain the viral fitness through stabilizing the F protein [25] [26] [27] . In comparison, peptide candidates such as 3ac against respiratory syncytial virus targeted the 6B complex to inhibit the post-fusion stage. Therefore, it was reported that the antiviral activity of the 3ac peptide would not be diminished against RSV escape mutants [28] .

Likewise, antivirals developed against EV-A71 have faced great challenges of resistance. A test compound ribavirin was reported to induced resistant mutants in cultures after several passages of the virus in its presence. Mutations such as S264L, G64R, G64T in the 3D polymerase were identified as the prime reason for reduced susceptibility of EV-A71 towards ribavirin [29] . Similarly, I113M and V123I mutations in the VP1 gene were detected upon serial passaging of the virus in the presence of new capsid binding pyridyl imidazolidinone-based small molecules (NLD and ALD) [30] .

One of the solutions to avoid resistance against EV-A71 is to switch the inhibitory target from viruses to the host. The relatively shorter half-life of the peptide could be favourably exploited by using small peptides that could bind to receptors used by viruses for entry into the cells. The peptide would degrade faster than chemical molecules and leave the biological system without harmful toxic compounds that are usually generated by small molecules. Tan et al. (2012) identified the SP40 peptide that could potentially inhibit J o u r n a l P r e -p r o o f the receptor(s) involved in the entry of EV-A71 into the host cell [31] . However, the exact receptor involved is currently under investigation. He et al. (2018) also identified a small peptide (RGDS) that blocked the fibronectin receptor and inhibited the viral entry of EV-A71 [32] . Nonetheless, these peptides are required to be further evaluated and modified to improve the stability and systemic bioavailability before they could be proposed as antiviral peptides for clinical use.

Peptides appear to be potential antiviral drugs but it has to overcome some obstacles. One of the main hurdles associated with peptides is the high cost of production.

Using short peptides such as RGDS, an antiviral peptide against EV-A71, would be more favourable to reduce the cost of production, Moreover, identification of minimal residues necessary for antiviral activity can be achieved by evaluating the truncated peptides of an identified antiviral peptide. Newer methods of peptide synthesis and purification methods of amides as well as production from recombinant peptide expression could be exciting approaches to mass-produce the antiviral peptides.

Apart from the cost of production, some of the major limitations associated with peptides are stability, bioavailability, short half-life and mode of delivery. Peptides are poor candidates to cross the physiological barrier [33] . Hence, therapeutic peptides are usually administered via subcutaneous, intramuscular or even intravenous routes to overcome the poor ability to cross the physiological barrier. A well-known example is an antiviral In general, a drug must have at least 20% of oral bioavailability in the body.

However, peptides can hardly achieve 1% bioavailability, making them a poor candidate as oral therapeutics. Poor bioavailability in combination with s shorter half-life makes peptide concentrations to be unavailable in systemic circulation for pharmacological effects. For example, the short half-life of ~4 hours of Enfuvitide could be overcome by chemical modifications that could pave the way for the development of future antiviral peptides as effective therapeutic agents [35] . Many factors can contribute to the instability of peptides in the physiological system. Enzymes such as hydrolases, proteases and peptidases are ubiquitously present in the body. When a peptide enters the biological system, it could rapidly be degraded by these enzymes. Moreover, physical barriers in the mucosal membrane, endocytosis and efflux pumps could greatly impact the bioavailability of peptides [36] .

Apart from peptides being given intravenously, all other routes of administrations could lead to rapid metabolism by enzymes at the site of administration when injected J o u r n a l P r e -p r o o f subcutaneously, intramuscularly or through the first-pass metabolism in the liver when administered by oral routes. This results in a sharp decline in the concentration of peptide drugs in the body, leading to poor pharmacodynamics profile of therapeutic peptide [37] .

Some of these limitations could be overcome by using strategies such as chemical modifications and nanosciences which are discussed later in section 5.

Therapeutic peptides were traditionally derived from plants and animals. With the advancement of technology, peptides responsible to protect humans from various microorganisms were identified/isolated from screening recombinant/peptide array libraries or those synthesised de novo [34] . The de novo peptides could also be found against a specific target by docking peptide libraries or rationally synthesising peptides using structural biology-based approaches. Several antiviral peptides isolated from natural resources have been documented against diverse groups of viruses [38] [39] [40] . Similarly, many peptides have been demonstrated to exhibit antiviral properties against enteroviruses [41, 42] . Antivirals against EV-A71 are discretely discussed in section 4.

Alloferon (HGVSGHGQHGVHG), a well-characterised peptide isolated from the blowfly, and its derivatives were evaluated for their antiviral activities against Coxsackie type B2 (CV-B2) 971 PT virus and a clinical isolate of CV-B2. It was identified that J o u r n a l P r e -p r o o f substitution of histidine at position 1 with lysine (Lys1-alloferon) could drastically improve the activity of alloferon and it was able to confer replication inhibition against CV-B2 971

PT and its clinical isolate [38] . However, the off-target effects of alloferon on other immune responses could be disadvantageous. Another naturally occurring peptide, melittin, was identified from the honeybee (Apis mellifera) venom and was reported to inhibit the CV-H3 infection in vitro. The inhibitory mechanism was found to be virucidal [43] .

Similarly, natural antimicrobial peptides produced by the normal flora of human gut lining such as human β-defensin 3 (hBD3) was found to be up-regulated during picornavirus infections, indicating a natural extracellular antiviral response. It was reported that poliovirus-1, CV-A16 and CV-B5 infections were inhibited significantly by hBD3 in vitro [44] . This is consistent with earlier reports of mouse β-defensin 3 that was identified to protect HeLa cells in vitro and myocarditis in mice from CV-B3 infection [45] .

Milk proteins and peptides have been widely studied for their antiviral activities against several viruses. One of the extensively studied proteins is lactoferrin and a small peptide lactoferricin derived from the N-terminal region of lactoferrin. Lactoferrin binds either to the structural proteins of viruses or to the receptor(s) of host cells [46] . In both circumstances, it could prevent viral attachment and/or internalisation. Marchetti et al. (1999) reported that lactoferrin has the potential to affect poliovirus replication in vitro.

Many lactoferrin derivatives including apo-lactoferrin, iron, zinc and manganese saturated J o u r n a l P r e -p r o o f lactoferrins were able to prevent the entry of poliovirus in Vero cells [47] . It was interesting to note that not human lactoferrin but bovine lactoferrin was able to provide relatively better antiviral effects against poliovirus [48] . In another study by Tinari et al. (2005) , bovine lactoferrin was found to inhibit the replication of echoviruses by blocking viral interaction with the receptor and prevented apoptosis in the cells infected with echoviruses [39] . The exact mechanism for lactoferricin is unclear for enteroviruses. However, it was proposed to interfere with host cell microtubules and reduced intergrase nuclear distribution in the case of HSV-1 and HIV-1, respectively [49, 50] .

Proteolytic cleavage inhibitor peptides play an important role in the reduction of 

Viruses causing HMFD generally infect children under the age of 6 years. 

The Moreover, lactoferrin was able to induce IFN-α and reduced virus-induced IL-6 production in SK-N-SH cells. It must be noted that only the preincubation of cells with lactoferrin was able to confer antiviral activity. The longer the preincubation time, the better the antiviral activity was observed in vitro [54] .

When tested in the murine model, lactoferrin on its own conferred 30% protection when seven-day-old mice were challenged with EV-A71 [46] . It was interesting to note that when the plasmid carrying the lactoferrin gene was injected into transgenic mother mice, 100% of the pups were able to survive EV-A71 lethal challenge on the seventh day since birth. However, when pups were challenged on the second day and fourth day of birth, the lethality was 50% and 33.3%, respectively. The viral loads were significantly reduced as shown by the reduction of viral RNA copies determined by RT-PCR which validated the earlier reports that oral lactoferrin could protect the suckling pups from EV-A71 infection [55] . The comparison of both studies suggested that when 5mg lactoferrin was directly administered to young mice, the lower protection observed was probably due to insufficient lactoferrin. When lactoferrin was continuously expressed from mother mice harboring the recombinant plasmid containing the lactoferrin gene, the quantity of lactoferrin present in the milk was significantly higher. This enhanced production of lactoferrin could confer the higher protection being observed. However, it must be stressed that even passive lactoferrin was unable to provide complete protection to less than a week old pups.

J o u r n a l P r e -p r o o f

Bee venom has been widely studied for the presence of several antimicrobial peptides including mast cell degranulating peptide, apamin, melittin and adolapin. When bee venom was evaluated for the antiviral activity against EV-A71 in vitro, it was found that bee venom can exert highly potent antiviral effects at as low as 2.0 μg/mL concentration. It was interesting to note that the highest concentration of melittin used in these experiments was only 2.0 μg/mL, indicating that the peptide was highly potent. However, melittin was found to be very toxic to cells at low concentrations as it could cause 50% cell death at 4.36 μg/mL [43] .

Host defensive peptides are expressed by upregulation of pro-inflammatory cytokines which is a classic immune response when toll-like receptors interact with pathogens. However, not many peptides were known to upregulate during EV-A71 infection is yet to be identified [31] .

Peptides G1 and G2 were previously shown to reduce the HSV infection by against EV-A71. When rhabdomyosarcoma cells were pre-incubated with peptides for 1 hour before EV-A71 infection, peptide G2 but not G1, was able to inhibit EV-A71 infection by up to 76.5% at 1,000 µg/mL, as determined by plaque assay and qRTPCR [58] .

However, the concentration at which this inhibition was achieved is far too high and therefore, it might require significant chemical modifications before it could be further considered as a potential candidate. replication [60] . It was interesting to find that not only antiviral-FLIP but also anticellular-FLIP was able to render marked antiviral activity. They also identified that the most critical amino acid residues Leu-Phe-Leu (LFL) within the functional domain of the peptide that were involved in protein-protein interactions for antiviral activity.

The process of viral replication generally requires priming to start the replication of the genome. In the case of EV-A71, a small peptide (VPg or 3B) is used as a primer for this purpose. The primer undergoes the process of uridylylation, where uridine residue is added to the molecule. VPg is required to be uridylylated before it could bind to 3D polymerase of EV-A71 for replication. Lou et al. (2014) reported that inhibition of VPg uridylylation could halt the replication of EV-A71. A small peptide of ten amino acids was found to inhibit the process of uridylylation and it was proposed as a potential antiviral candidate against EV-A71 [61] . Conversely, very limited information is available in the literature regarding this peptide and thus necessities further in-depth study. Moreover, the efficacy of this peptide was evaluated in suckling mice. The peptide was found to confer 75% survival of newborn mice up to day 13 due to decreased viral loads.

Moreover, marked improvement was observed in body weights and clinical scores of RGDS treated pups [32] . However, the concentration of RGDS peptide for treatment at 5 mg/kg in mice was high and this could pose a problem for clinical application.

An understanding of the molecular mechanisms involved in various stages of EV-A71 infection could lead to the rational design of antivirals. The molecules that have been J o u r n a l P r e -p r o o f shown to modulate virus pathogenesis or inhibiting virus entry by competing with cell attachment factors for binding to EV-A71 could be ideal candidates. Antiviral peptides known to inhibit EV-A71 are presented in Table 3 .

J o u r n a l P r e -p r o o f 27 food. Peptide molecules that succeed in passing through these barriers can also encounter efflux pumps that may reverse their flow back into the intestine. Presystemic first-pass metabolism through portal vein and liver is yet another challenge for oral delivery of peptides which decreases bioavailability. Even potent peptide drugs given orally will have short half-lives (usually in minutes) due to rapid clearance from the system. This may result in the necessity for increased frequency of dosage and led to reduced patient compliance.

Currently, only 9 peptides are marketed in the oral dosage form (Table 4 ) but there is none against viral infections [62] . Retro-inverso peptide is another way of modification from L-to D-conformation by flipping the peptide sequence from the C to N terminal region [66] . Levi et al. (2004) identified a peptide from the HIV antibody representing the specific complementaritydetermining region. This peptide was entirely changed to non-natural D-amino acids and retro-inversed to reduce the susceptibility to enzymatic degradation. This peptide showed greater inhibition than its L-peptide [67] .

Another approach to protecting a peptide from enzymatic degradation is cyclisation. It was demonstrated to increase the half-life of a peptide by Werle et al. (2006) [68] . Cyclisation can be achieved by different kinds of chemical bridging such as biaryl, disulphide ether bridges [63, 69] . Peptides were derived from complementaritydetermining region loops present in broad-spectrum antibodies against various influenza J o u r n a l P r e -p r o o f virus strains. The design used cyclisation and non-proteogenic amino acids to improve the pharmacokinetic and therapeutic spectrum of antiviral peptides [70] . However, it must be kept in mind that cyclisation could make peptide structure rigid and might render it inactive in some cases [63] . [72] .

Similarly, protein lipidization was found to confer stability and thus prolonged half-life. This is due to the facilitation of transport of the peptides through membranes.

Reduced peptide bonds, pseudo peptides, nitrogen substitution at the α-carbon in the backbone are some of the other ways towards producing superior oral peptides [63] .

Stapled peptides are α-helical peptides with linking residues on the backbone of hydrocarbon chain usually at position i and i + 3, i + 4 or i + 7. These linking residues are olefinic amino acids (UAA) and do not hamper the interactions between peptides J o u r n a l P r e -p r o o f and targets [24] . Stapling has been demonstrated to improve plasma half-life owing to resistance to proteases in vitro and in vivo [73] .

Currently, most peptides are administered as injectables and the challenges facing oral administration include acidic and enzymatic degradation in the gastrointestinal tract as well as their ability to cross the intestinal mucosa. Chemical modifications of peptides for oral administration include stapling of peptides, building hydrophobic patches, cyclisation, amidation or acetylation, methylation and establishment of hydrogen bonds [36] .

To facilitate the oral delivery of peptides, many carriers have been studied. It may or may not be accompanied by absorption enhancers or enzyme inhibitors. [74] . SNAC has been used to deliver peptides in vitro and by the oral route in the animal model. B12™ is a marketed product that has used SNAC as an oral delivery agent [75] . Insulin and GLP-1 analogues have also been reported to use conjugation with SNAC to formulate the oral J o u r n a l P r e -p r o o f dosage form and they have reached a clinical trial phase I [76] . Peptelligence®, Robotic pill®, Nanocells® are other technology platforms currently in use by pharmaceutical industries to boost oral delivery of peptides [77] . Similarly, lipid-based nanosuspensions are becoming popular delivery agents for in vitro and in vivo administration and have been studied extensively to develop an improved carrier system for clinical settings [78] .

The cell membrane is a natural selective barrier preventing the entry of peptides into the cell. Cell-penetrating peptides (CPPs) which are positively charged short peptides (5-30 amino acids) have been shown to penetrate the biomembrane and delivering peptides for intracellular functions, both in vitro and in vivo. CPPs could enter the cells directly by transduction through the membrane (pore formation or membrane destabilisation) or undergo endocytosis (including micropinocytosis) [79] .

CPP shuttles could be chemically synthesised or be driven from known proteins (for example, the TAT protein). Many CPPs are currently undergoing clinical trials for evaluation to transport peptide cargoes against various diseases [80] .

With the success of Enfuvirtide as an antiviral peptide, there is a great potential that other peptide drugs can enter the clinical setting. However, the challenges associated with drug delivery require attention. The nanomaterials that could enhance the oral delivery of peptide-based drugs have been reviewed [81] . Enhanced antiviral effects could be brought about through the use of conventional enzyme inhibitors, chelators, protease inhibitors encapsulated in nanomaterials to the most recently reported biodegradable microneedles drug cargoes. Nanoparticles made of polymeric J o u r n a l P r e -p r o o f particles such as lactic acid, ester amides and fatty acid esters provide hydrophobic interactions, thus allowing increased retention time at the mucosal lining. Inorganic particles such as gold, silica and selenium provided better drug release profiles when compared to polymeric particles due to their ability to withstand the acidic environment.

The factors in successful oral peptide delivery may also involve diameter, surface charge and surface modifications of nanoparticles. Moreover, peptide ligand modification, loading with CPP or RGDS peptide and nanocrystalisation have been proposed as some of the ways to improve the penetration, stability and long-term retention of biological activity [82] . Nanocrystallisation or nanosuspension of the pure therapeutic drug has the advantage of 100% drug delivery. Nanoformulations also allow masking the taste of drugs and therefore, can quickly be adapted for drugs that require long term usage for specific groups of population such as the paediatric and geriatric patients to increase the compliance rate of therapy [22] . Nanoparticles can affect the pharmacokinetics, pharmacodynamics and therapeutic characteristics of encapsulated drugs along with improved safety [82] . Nanoparticles can also be considered as an option to address the challenges of manufacturing thermolabile or easily degradable peptides and thus allow nanodrugs to move towards clinical applications [22] .

Many antiviral candidates including small molecules, antibodies and natural compounds have been discontinued for clinical development due to the increasing emergence of resistant mutants. Peptide therapeutics can be an alternative approach to overcome the emergence of resistance by targeting essential processes of pathogenesis or entry into the host cells. Peptides have an advantage over many small molecule drugs as the latter could only interact with a limited area of the target and this interaction 

SARS-CoV-2 vaccines: status report

Hand, foot, and mouth disease in China, 2008-12: an epidemiological study

Approved antiviral drugs over the past 50 years

Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019

An investigation of the antiviral activity of Podophyllum peltatum

Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice

Flavonoids as antiviral agents for Enterovirus A71 (EV-A71)

The role of natural products in modern drug discovery

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy

Therapeutic peptides

Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs

Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress

Antiviral peptides as promising therapeutic drugs

Antiviral peptides targeting the West Nile virus envelope protein

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections

Cationic antimicrobial peptides: towards clinical applications

Peptide antiviral strategies as an alternative to treat lower respiratory viral infections

Molecular mechanism of respiratory syncytial virus fusion inhibitors

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Analysis of GS-5806 resistance emergence in human healthy adult subjects experimentally infected with respiratory syncytial virus (RSV)

A short double-stapled peptide inhibits respiratory syncytial virus entry and spreading

Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture

Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16

Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1

Fibronectin facilitates enterovirus 71 infection by mediating viral entry

Lead-and drug-like compounds: the rule-of-five revolution

An Update-Prolonging the action of protein and peptide drugs

Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches

Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides

Further studies on the antiviral activity of alloferon and its analogues

Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro

Peptides to combat viral infectious diseases

The antimicrobial peptides and their potential clinical applications

Human antimicrobial peptides as therapeutics for viral infections

Inhibitory effects of bee venom and its components against viruses in vitro and in vivo

Induction and antiviral activity of human β-defensin 3 in intestinal cells with picornavirus infection

Recombinant Mouse β-Defensin 3 Protects against Coxsackievirus B3-Induced Myocarditis in Mice

Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells

Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells

The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures

Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides

Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate

Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections

Targeting enteroviral 2A protease by a 16-mer synthetic peptide: inhibition of 2Apro-induced apoptosis in a stable Tet-on HeLa cell line

Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from

Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro

Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonatal mice from a lethal challenge with enterovirus type 71

Cellular receptors for Enterovirus A71

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor

Blocking human enterovirus 71 replication by targeting viral 2A protease

Antiviral protection against enterovirus 71 mediated by autophagy induction following FLICEinhibitory protein inactivation

Current progress in antiviral strategies

Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials

Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization

Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB

Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy

Recent developments in retro peptides and proteins-an ongoing topochemical exploration

A retro-inverso miniantibody with anti-HIV activity

Strategies to improve plasma half life time of peptide and protein drugs

Structure-based design of an indolicidin peptide analogue with increased protease stability

Potent peptidic fusion inhibitors of influenza virus

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pancoronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic

Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects

Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Oral peptide delivery: technology landscape and current status

Lipid-based nanosuspensions for oral delivery of peptides, a critical review

Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells

Cell-penetrating peptides: from basic research to clinics

Materials for oral delivery of proteins and peptides

Nanoparticles: oral delivery for protein and peptide drugs

The publication of this paper was through partial funding by Sunway University to support research projects in the Centre for Virus and Vaccine Research (CVVR) for 2020. We acknowledge that this work has been produced under the support from FRGS